Short answer
CG Oncology, Inc. (CGON) filed an 8-K current report with the SEC on April 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Jim DeTore appointed CFO on April 13, 2026, formalizing leadership after serving as interim principal financial and accounting officer since November 2025.
CG Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jim DeTore appointed CFO on April 13, 2026, formalizing leadership after serving as interim principal financial and accounting officer since November 2025
- Base salary $520,000 with 45% annual target bonus, increasing fixed and incentive compensation commitments
- Initial equity package targets $4 million in stock options and $1 million in performance stock units
- PSU vesting tied to first product commercialization and positive operating cash flow for two consecutive quarters
- Severance reaches 1.5 times base salary plus full equity acceleration after qualifying termination during a change-in-control period
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CG Oncology, Inc. 8-K filings
Get the next CGON 8-K as it lands
Follow CGON for push alerts, or ask the research agent what this filing means.